Lansoprazole

Brand names: Prevacid · Active ingredient: Lansoprazole

In short: Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer . Triple Therapy: Lansoprazole /amoxicillin /clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clar

Forms & strengthsLansoprazole delayed-release capsules, USP: • 15 mg capsules are white to off white, spherical to oval pellets filled in hard gelatin capsule shells of size 3 with " " imprinted in grey ink on green opaque colored cap and “806” imprinted in black ink on white …
LabelLifestar Pharma LLC.
Label updatedNov 02, 2026

What is Lansoprazole used for?

Lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer

.

Triple Therapy: Lansoprazole /amoxicillin /clarithromycin

Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with

H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate

H. pylori. Eradication of

H. pylori has been shown to reduce the risk of duodenal ulcer recurrence

.

Please refer to the full prescribing information for amoxicillin and clarithromycin.

Dual Therapy: Lansoprazole /amoxicillin

Lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with

H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer)

who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected . Eradication of

H. pylori has been shown to reduce the risk of duodenal ulcer recurrence

.

Please refer to the full prescribing information for amoxicillin.

Lansoprazole delayed-release capsules are indicated in adults to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months

. …

Lansoprazole dosage

Indication | Recommended

Dose | Frequency

Duodenal Ulcers

Short-Term Treatment

Maintenance of Healed | 15 mg

15 mg | Once daily for 4 weeks

Once daily

Eradication of

H

.

pylori to Reduce the Risk of Duodenal Ulcer Recurrence

Please refer to the amoxicillin and clarithromycin full prescribing information,

Contraindications and

Warningsand Precautions sections, and for information regarding dosing in elderly and renally-impaired patients.

Triple Therapy:

Lansoprazole

Amoxicillin

Clarithromycin

Dual Therapy:

Lansoprazole

Amoxicillin | 30 mg

1 gram

500 mg

30 mg

1 gram | Twice daily for 10 or 14 days

Twice daily for 10 or 14 days

Twice daily for 10 or 14 days

Three times daily for 14 days

Three times daily for 14 days

Benign Gastric Ulcer

Short-Term Treatment | 30 mg | Once daily for up to 8 weeks

NSAID-Associated Gastric Ulcer

Healing

Risk Reduction | 30 mg

15 mg | Once daily for 8 weeks

Controlled studies did not extend beyond indicated duration.

Once daily for up to 12 weeks

Gastroesophageal Reflux Disease (GERD)

Short-Term Treatment of

Symptomatic GERD

Short -Term Treatment

of Erosive Esophagitis | 15 mg

30 mg | Once daily for up to 8 weeks

Once daily for up to 8 weeks

For patients who do not heal with lansoprazole for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis, an additional eight week course of lansoprazole may be considered.

Maintenance of Healing of

Erosive Esophagitis | 15 mg | Once daily

Controlled studies did not extend beyond 12 months

Pathological Hypersecretory

Conditions Including

Zollinger-Ellison Syndrome | 60 mg | Once daily

Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg twice daily have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with lansoprazole for more than four years.

Pediatric Patients 1 to 11 Years of Age

In clinical studies, lansoprazole was not administered beyond 12 weeks in 1 to 11 year olds. It is not known if lansoprazole is safe and effective if used longer than the recommended duration. Do not exceed the recommended dose and duration of use in pediatric patients as outlined below

. …

How to take Lansoprazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Advise patients to:

Acute Tubulointerstitial Nephritis

To call their healthcare provider if they experience signs and/or symptoms associated with acute tubulointerstitial nephritis

.

Clostridium difficile-Associated Diarrhea

To immediately call their healthcare provider if they experience diarrhea that does not improve

Bone Fracture

To report any fractures, especially of the hip, wrist or spine, to their healthcare provider

Severe Cutaneous Adverse Reactions

To discontinue lansoprazole delayed-release capsules and immediately call their healthcare provider for further evaluation

. …

Warnings & precautions

Do not take this medicine if: Lansoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria

.

Proton Pump Inhibitors (PPIs), including lansoprazole, are contraindicated with rilpivirine-containing products

.

For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with lansoprazole, refer to the

Contraindications section of their prescribing information.

In adults, symptomatic response to therapy with lansoprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.

Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia). In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Discontinue lansoprazole and evaluate patients with suspected acute TIN

.

Published observational studies suggest that PPI therapy like lansoprazole may be associated with an increased risk of

Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve

.

Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. …

Lansoprazole side effects

The following serious adverse reactions are described below and elsewhere in labeling:

Acute Tubulointerstitial Nephritis

Clostridium difficile-Associated Diarrhea

Bone Fracture

Severe Cutaneous Adverse Reactions

Cutaneous and Systemic Lupus Erythematosus

Cyanocobalamin (Vitamin B

12) Deficiency

Hypomagnesemia and Mineral Metabolism

Fundic Gland Polyps

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Worldwide, over 10,000 patients have been treated with lansoprazole in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment. In general, lansoprazole treatment has been well-tolerated in both short-term and long-term trials.

The following adverse reactions were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of lansoprazole -treated patients and occurred at a greater rate in lansoprazole-treated patients than placebo-treated patients in

Table 1.

Body System/Adverse

Reaction | Lansoprazole

(N= 2768)

% | Placebo

(N= 1023)

%

Body as a Whole

Abdominal Pain | 2.1 | 1.2

Digestive System

Constipation

Diarrhea

Nausea | 1.0

3.8

1.3 | 0.4

2.3

1.2

Headache was also seen at greater than 1% incidence but was more common on placebo. …

Drug interactions

Tables 2 and 3 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with lansoprazole delayed-release capsules and instructions for preventing or managing them.

Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.

Antiretrovirals

Clinical Impact: | The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.

Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance.

Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with lansoprazole may increase toxicity of the antiretroviral drugs.

There are other antiretroviral drugs which do not result in clinically relevant interactions with lansoprazole.

Intervention: | Rilpivirine-containing products: Concomitant use with lansoprazole is contraindicated

. See prescribing information.

Atazanavir : See prescribing information for atazanavir for dosing information.

Nelfinavir: Avoid concomitant use with Lansoprazole. …

About this medicine

The active ingredient in Lansoprazole Delayed-Release Capsules, USP is lansoprazole USP, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C

16H

14F

3N

3O

2S with a molecular weight of 369.37. Lansoprazole has the following structure:

Lansoprazole USP is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Lansoprazole USP is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID afcc0f14-8b00-41ac-8e62-4094a15b959c. Read the full official label on DailyMed.

Related medicines

Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate